BeyondSpring Inc.

BYSI ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023
Revenue $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $4.4M $2.6M $7.3M
SG&A Expense $4.6M $6.1M $7.8M
Operating Income $-8.9M $-8.8M $-15.1M
Operating Margin
Interest Expense
Pretax Income $-8.6M $-8.8M $-13.9M
Income Tax Expense $90.0K $96.0K $-92.0K
Net Income $-1.0M $-11.1M $-21.0M
Net Margin
EPS (Basic) $-0.02 $-0.28 $-0.54
EPS (Diluted)
Shares Outstanding (Basic) 41.1M 41.1M 40.3M 39.0M
Shares Outstanding (Diluted) 41.1M 41.1M 40.3M 39.0M
Dividends Per Share